Insmed To Present at September Investor Conferences
Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Wells Fargo 2025 Healthcare Conference in Boston on September 5 at 8:00 a.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9 at 4:50 p.m. ET.
Both presentations will be available via webcast through Insmed's investor relations website and will remain accessible for 30 days after the events.
Insmed (Nasdaq: INSM), azienda biofarmaceutica globale, ha annunciato la sua partecipazione a due conferenze per investitori previste a settembre 2025. La societ脿 interverr脿 al Wells Fargo 2025 Healthcare Conference a Boston il 5 settembre alle 8:00 ET e al Morgan Stanley 23rd Annual Global Healthcare Conference a New York il 9 settembre alle 16:50 ET.
Entrambe le presentazioni saranno trasmesse via webcast tramite il sito web delle relazioni con gli investitori di Insmed e resteranno disponibili per 30 giorni dopo gli eventi.
Insmed (Nasdaq: INSM), una compa帽铆a biofarmac茅utica global, ha anunciado su participaci贸n en dos pr贸ximas conferencias para inversores en septiembre de 2025. La compa帽铆a presentar谩 en el Wells Fargo 2025 Healthcare Conference en Boston el 5 de septiembre a las 8:00 a.m. ET y en el Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York el 9 de septiembre a las 4:50 p.m. ET.
Ambas presentaciones estar谩n disponibles por webcast a trav茅s del sitio web de relaciones con inversores de Insmed y permanecer谩n accesibles durante 30 d铆as despu茅s de los eventos.
Insmed (Nasdaq: INSM)鞚� 旮�搿滊矊 氚旍澊鞓れ牅鞎� 須岇偓搿滌劀 2025雲� 9鞗旍棎 臧滌禍霅橂姅 霊� 瓯挫潣 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 9鞗� 5鞚� 鞓れ爠 8:00 ET鞐� 氤挫姢韯挫棎靹� 鞐措Μ電� Wells Fargo 2025 Healthcare Conference鞕� 9鞗� 9鞚� 鞓ろ泟 4:50 ET鞐� 雺挫殨鞐愳劀 鞐措Μ電� Morgan Stanley 23rd Annual Global Healthcare Conference鞐愳劀 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
霊� 氚滍憸 氇憪 Insmed鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌ 頄夓偓 膦呺 頉� 30鞚缄皠 雼れ嫓氤搓赴搿� 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Insmed (Nasdaq: INSM), une entreprise biopharmaceutique mondiale, a annonc茅 sa participation 脿 deux conf茅rences pour investisseurs pr茅vues en septembre 2025. La soci茅t茅 pr茅sentera au Wells Fargo 2025 Healthcare Conference 脿 Boston le 5 septembre 脿 8h00 ET et au Morgan Stanley 23rd Annual Global Healthcare Conference 脿 New York le 9 septembre 脿 16h50 ET.
Les deux pr茅sentations seront diffus茅es en webcast via le site des relations investisseurs d'Insmed et resteront accessibles pendant 30 jours apr猫s les 茅v茅nements.
Insmed (Nasdaq: INSM), ein globales biopharmazeutisches Unternehmen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 angek眉ndigt. Das Unternehmen wird am Wells Fargo 2025 Healthcare Conference in Boston am 5. September um 8:00 Uhr ET und am Morgan Stanley 23rd Annual Global Healthcare Conference in New York am 9. September um 16:50 Uhr ET pr盲sentieren.
Beide Pr盲sentationen werden per Webcast 眉ber die Investor-Relations-Website von Insmed verf眉gbar sein und f眉r 30 Tage nach den Veranstaltungen abrufbar bleiben.
- None.
- None.
- Wells Fargo 2025 Healthcare Conference in
Boston , on Friday, September 5, 2025, at 8:00 a.m. ET. - Morgan Stanely 23rd Annual Global Healthcare Conference in
New York , on Tuesday, September 9, 2025, at 4:50 p.m. ET.
These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at聽www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and in铿俛mmatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Bryan
Vice President, Investor Relations
(646) 812-4030
[email protected]
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
[email protected]
View original content to download multimedia:
SOURCE Insmed Incorporated
FAQ
When is Insmed presenting at the Wells Fargo Healthcare Conference 2025?
What time is Insmed's presentation at the Morgan Stanley Healthcare Conference 2025?
How can investors access Insmed's September 2025 conference presentations?
How long will Insmed's September 2025 conference webcasts be available?
